Thursday's ETF Movers: XBI, SIL

BBH: Buy Rating, As Tech Investors Look Beyond FAANG

VanEck Biotech ETF tracks top U.S.-listed biotech companies, offers exposure to innovative therapies and technologies. Biotechnology sector experiencing exponential growth driven by emerging technologies addressing global challenges. The VanEck biotech ETF (BBH) is under-discovered compared to peers, offers potential for trend change in biotech sector.

Biotech ETF (XBI) Rallied from the Blue Box Hitting Target

The SPDR S&P Biotech ETF (XBI) is an exchange-traded fund that tracks the biotechnology segment of the S&p Total Market Index. XBI is expected to continue the bullish movement. The next target for XBI comes around 108.85.

Weekly Report: what happened at XBI last week (0715-0719)?

Notable ETF Outflow Detected - XBI, EXAS, SRPT, UTHR

Small-cap stocks are perking up. Here’s how to pick winners. 

Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report

Regeneron Pharmaceuticals, Inc. (REGN) is set to announce its fiscal Q2 earnings results before the market opens on Thursday, Aug. 1. The company is expected to report a profit of $8.89 per share. REGN reported Q1 earnings on May 2. The stock is up 23.6% on a YTD basis.

HQH: Discount Remains Attractive With A Now Higher Distribution Rate

Abrdn Healthcare Investors Fund focuses on the more cyclical biotech space, with over half of its portfolio allocated there. The fund's managed distribution policy was increased significantly since our prior update. The abrdn healthcare investors fund continues to trade at an attractive discount. Discount Narrows With Distribution Increase But Remains Appealing.

ASCO Annual Meeting 2024: Breakthrough Treatments Hint At Renewed Hope For Patients And Investors

How The Pieces Add Up: XBI Targets $140

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

Weekly Report: what happened at XBI last week (0708-0712)?

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Notable ETF Inflow Detected - XBI, SRPT, UTHR, ALNY

Neuralink to implant brain device in second patient within weeks

Elon Musk's Neuralink to implant brain device in second patient within weeks. The company implanted its brain-computer interface device in its first patient earlier this year. The recipient is quadriplegic and uses the device to read and play video games. Musk says the company hopes to implant the device in a second patient in the next few weeks.

Biotech Stocks 2024 Second Half Outlook - Buy Biotechs

Biotech indexes lagged broader market indexes in the first half of 2024. Biotech valuations are closely tied to the Fed's interest rate policy and are highly correlated to the 10-year yield. Inflation is likely to trend lower, and the Fed is expected to cut rates in September. The second half of 2024 holds potential for biotech stocks to break out of their consolidation.

Surprising Analyst 12-Month Target For XBI

Weekly Report: what happened at XBI last week (0701-0705)?

Global Anti-Obesity Market Analysis: Key Trends And Insights

SBIO, XBI, or BBP: Which is the Best Biotech ETF, According to Analysts?